TM6SF2
TM6SF2 is a key regulator of hepatic VLDL secretion. The E167K variant creates a famous metabolic paradox: it increases the risk of fatty liver (steatosis) while simultaneously protecting against cardiovascular disease.
Key Takeaways
- •TM6SF2 is essential for the normal secretion of triglyceride-rich VLDL particles from the liver.
- •The E167K variant (rs58542926) is a loss-of-function mutation that traps fat in the liver but lowers blood cholesterol.
- •Carriers of the E167K variant have a ~30% lower risk of heart disease but a significantly higher risk of NAFLD/MASH.
- •Precision management involves balancing liver health (sugar/alcohol restriction) with the carrier's natural cardiovascular advantage.
Basic Information
- Gene Symbol
- TM6SF2
- Full Name
- Transmembrane 6 Superfamily Member 2
- Location
- 19p13.11
- Protein Type
- VLDL Assembly Regulator
- Protein Family
- Transmembrane 6 superfamily
Related Isoforms
Key SNPs
Encodes E167K; a loss-of-function variant that causes fatty liver but protects against heart disease.
An eQTL marker associated with TM6SF2 expression levels in the liver.
Overview
TM6SF2 (Transmembrane 6 Superfamily Member 2) is a protein localized to the ER-Golgi intermediate compartment (ERGIC) of hepatocytes. Its primary job is to act as a "docking master" for the assembly and secretion of Very Low-Density Lipoprotein (VLDL) particles. By stabilizing Apolipoprotein B (APOB) and facilitating the loading of triglycerides, TM6SF2 ensures that fat produced or processed in the liver is efficiently exported into the bloodstream.
TM6SF2 is most famous for the "NAFLD-CVD Paradox." A common genetic variant, E167K, impairs the protein's function. This creates a bottleneck: fat cannot leave the liver (causing steatosis) but consequently, fewer cholesterol-carrying particles enter the blood (protecting the heart).
Conceptual Model
A simplified mental model for the pathway:
In the E167K variant, the "crane" is broken; fat stays at the dock (liver) and the ships (LDL) never sail.
Core Health Impacts
- • Lipid Export: Essential for the efficient export of triglycerides from hepatocytes
- • Vascular Protection: Loss-of-function variants lower circulating LDL-C and APOB levels
- • Liver Health: Mutations increase the risk of progressive liver fat and fibrosis
- • Cholesterol Tone: Regulates the baseline "tone" of systemic lipid metabolism
- • ER Stress: Influences the level of protein-folding stress in the liver
Protein Domains
Transmembrane Segments
Contains 10 predicted transmembrane domains that anchor the protein in the ERGIC membrane.
APOB Interaction Loop
Specific lumenal loops that physically bind to nascent APOB particles to prevent their degradation.
Upstream Regulators
HNF4A Activator
Master transcriptional regulator of hepatic identity that binds the TM6SF2 promoter to drive expression.
Thyroid Hormone (T3) Activator
Signals through THR-β to promote TM6SF2-mediated VLDL assembly and lipid mobilization.
SREBP-1c Activator
Lipogenic transcription factor that correlates with TM6SF2 levels during high-fat feeding states.
Dietary Cholesterol Activator
Postprandial lipid influx triggers the need for TM6SF2-mediated APOB stabilization and VLDL export.
Downstream Targets
APOB (Apolipoprotein B) Activates
Physical target for stabilization; TM6SF2 prevents premature APOB degradation in the ER.
ERLIN1 / ERLIN2 Activates
Proteins that form a complex with TM6SF2 to facilitate nascent VLDL lipidation and assembly.
VLDL1 Particles Activates
The primary export vehicle for liver triglycerides; secretion is blocked in TM6SF2 deficiency.
Hepatic Triglycerides Activates
Cleared from the liver into the bloodstream when TM6SF2 is fully functional.
Circulating LDL-C Activates
Downstream product of VLDL; levels are significantly reduced in carriers of the E167K variant.
Role in Aging
TM6SF2 determines how the liver and the heart "age" in relation to lipid stress. While general aging typically involves both increasing liver fat and increasing arterial plaque, TM6SF2 carriers often show a divergent phenotype where one system is stressed and the other is spared.
Divergent Aging
TM6SF2 E167K carriers exhibit "accelerated liver aging" (steatosis/fibrosis) alongside "decelerated vascular aging" (low plaque burden).
Thyroid-Lipid Axis
The decline in thyroid sensitivity with age may worsen the lipid export defect in TM6SF2 carriers, leading to later-life surges in liver fat.
Lipotoxicity
Chronic retention of triglycerides in the liver drives lipotoxicity, which can mimic aging-related cellular damage in hepatocytes.
Vascular Longevity
By maintaining lower LDL-C from birth, TM6SF2 carriers gain a cumulative "area under the curve" advantage for vascular health.
Proteostasis Stress
Inefficient VLDL assembly in carriers can increase ER stress, a central hallmark of biological aging in metabolic tissues.
Regenerative Capacity
Chronic steatosis driven by TM6SF2 loss can impair the liver's ability to regenerate after injury as it ages.
Disorders & Diseases
MASLD (Fatty Liver)
E167K carriers have a ~2-fold increase in hepatic triglyceride content. The variant is a major genetic driver of MASLD and its more severe form, MASH.
Cardiovascular Protection
Paradoxically, the same variant that damages the liver reduces the risk of myocardial infarction by lowering systemic LDL-C and APOB levels.
Gallstone Disease
Alterations in hepatic lipid handling in TM6SF2 carriers may influence the composition of bile and the risk of cholesterol gallstones.
Hepatocellular Carcinoma
Like other steatosis-driving genes (PNPLA3), TM6SF2 loss-of-function is associated with an increased long-term risk of liver cancer.
The NAFLD-CVD Paradox
TM6SF2 highlights that what is "good" for the heart (low blood lipids) can sometimes be "bad" for the liver if the mechanism involves trapping those lipids in the organ.
Interventions
Supplements
Used to lower liver fat and support overall lipid metabolism in NAFLD contexts.
Antioxidant support for patients with advanced MASH (steatohepatitis).
Strong epidemiological evidence suggests regular coffee consumption is protective against cirrhosis and liver cancer.
Studied for its ability to modulate LDL receptors and improve hepatic lipid handling.
Lifestyle
High in healthy fats and low in refined sugars; the preferred dietary pattern for MASLD management.
Reduces hepatic fat fraction by improving whole-body fatty acid oxidation and insulin sensitivity.
Reduces de novo lipogenesis, lowering the triglyceride burden on an impaired export system.
Essential to prevent synergistic injury in patients with genetic liver risk variants.
Medicines
FDA-approved THR-β agonist that restores hepatic lipid mobilization; highly relevant for TM6SF2-deficient states.
Lower LDL-C; while carriers already have low LDL, statins may be used for additional CVD risk reduction if needed.
Promote weight loss and improve metabolic health, reducing the pressure on the liver's lipid export dock.
Investigational drugs that block the first step of fat synthesis, reducing the "trap" in TM6SF2-deficient livers.
Lab Tests & Biomarkers
Genetic Testing
Identifies the E167K variant to assess the risk of liver fat vs. cardiovascular protection.
Combines TM6SF2 with PNPLA3 and HSD17B13 for a comprehensive assessment of liver health.
Lipid Panels
A more precise marker of the VLDL export defect than standard LDL-C in TM6SF2 carriers.
Typically low or very low in carriers of the E167K variant.
Liver Assessment
Measures liver stiffness and fat (CAP) non-invasively; essential for monitoring TM6SF2 carriers.
Standard liver enzymes that may be chronically elevated in the presence of steatosis.
Hormonal Interactions
Thyroid Hormone Primary Activator
Essential for VLDL assembly and lipid export via THR-β activation of TM6SF2 pathways.
Estrogen Protective
Supports liver resilience; postmenopausal loss increases the risk of fibrosis for E167K carriers.
Insulin Metabolic Driver
High levels drive de novo lipogenesis, exacerbating hepatic fat accumulation in the presence of impaired export.
Deep Dive
Network Diagrams
TM6SF2 and the VLDL Export Dock
The Export Bottleneck: TM6SF2 and APOB
To understand TM6SF2, one must view the hepatocyte as a busy shipping port. Triglycerides (the cargo) must be loaded onto Apolipoprotein B (the ships) to be sent out to the rest of the body.
Stabilizing the Ship: TM6SF2 is located at the “loading dock”—the ER-Golgi intermediate compartment. Its primary role is to physically interact with nascent APOB. Without TM6SF2, the APOB “ship” is unstable and is often destroyed (degraded) before it can ever be loaded with fat.
The Lipidation Gap: TM6SF2 is specifically required for the second stage of VLDL assembly, where large amounts of triglycerides are added to the particle (forming VLDL1). When TM6SF2 is missing or mutated, the liver can still make small, lipid-poor VLDL2, but it cannot export the large, triglyceride-rich VLDL1 particles.
The NAFLD-CVD Paradox: A Genetic Trade-off
The TM6SF2 E167K variant provides one of the clearest examples of a metabolic trade-off in the human genome.
Liver Risk (NAFLD): Because fat export is blocked, triglycerides accumulate rapidly within the liver cells. Carriers of the E167K variant have significantly higher liver fat content and are more likely to progress from simple steatosis to inflammation (MASH) and fibrosis.
Heart Protection (CVD): However, because fewer VLDL particles are entering the blood, there are fewer precursors for the formation of LDL (the “bad” cholesterol). Carriers of the variant have lower circulating LDL-C and APOB levels, translating to a substantial lifelong protection against coronary artery disease.
Therapeutic Implications: Restoration vs. Compensation
The management of TM6SF2-related liver disease focuses on either restoring the export pathway or reducing the fat “cargo” that needs to be exported.
Thyroid Agonists: The recent approval of Resmetirom (a THR-β agonist) is highly relevant for TM6SF2 carriers. Thyroid hormone is a master inducer of the VLDL export machinery; by hyper-activating the remaining functional TM6SF2 pathways, these drugs can help “clear the dock” and reduce liver fat.
Upstream Blockade: Alternatively, drugs like ACC inhibitors focus on stopping the production of fat (lipogenesis) within the liver. By reducing the amount of cargo arriving at the dock, they prevent the bottleneck from causing cellular damage.
Ultimately, TM6SF2 teaches us that systemic lipid levels are only half the story; the location of those lipids—whether in the blood or the organ—is what determines the ultimate health outcome.
Practical Note: The Paradox in Practice
Low LDL is not always a sign of "perfect" health. In a TM6SF2 E167K carrier, extremely low LDL-C can be a sign that fat is being trapped in the liver. These individuals must focus on liver-sparing lifestyle choices (no fructose, limited alcohol) even if their heart disease risk appears non-existent.
Thyroid health is paramount. Because TM6SF2 is regulated by thyroid hormone, maintaining optimal T3 levels is especially important for E167K carriers to help maximize their remaining lipid-export capacity.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first identified the E167K variant and established its paradoxical role in liver and heart health.
Comprehensive meta-analysis confirming the cardioprotective effect of the fatty-liver-causing variant.
Detailed human kinetic study demonstrating that the E167K variant specifically blocks the export of triglyceride-rich VLDL1 particles.
Phase 3 trial results for the first FDA-approved MASH therapy, which targets the THR-β pathway upstream of TM6SF2.
Review of the protein's role in the ERGIC and its physical interaction with APOB.
Preclinical study showing that blocking de novo lipogenesis can mitigate the fat accumulation caused by TM6SF2 loss of function.